Cotinga Pharmaceuticals Reports Fiscal 2019 Second Quarter

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
30
Cotinga Pharmaceuticals Reports Fiscal 2019 Second Quarter Financial and Operating Results

TORONTO and BOSTON, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT; OTCQB: COTQF) (“Cotinga” or the “Company”) , a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, reported its financial and operating results today for the three and six months ended October 31, 2018. Recent highlights include:

Advanced the clinical development of COTI-2:

  • Cotinga continued its initiation of the combination therapy trial at MD Anderson Cancer Center evaluating COTI-2 and cisplatin in a wide spectrum of cancers.
  • The Company announced that it has entered into a research collaboration with St. Vincent’s University Hospital in Dublin, Ireland to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer (TNBC).

Presented scientific findings from its COTI-2 research and clinical program:

  • In September 2018, Cotinga presented data on COTI-2 at the 11 th International Symposium on Translational Research in Oncology in Dublin, Ireland.

“We continued to work hard during this fiscal quarter to initiate our clinical trial site at MD Anderson with an expanded protocol for our ongoing Phase 1b/2a trial of COTI-2, as well as announce our collaboration with St. Vincent’s Hospital to begin work in TNBC” said Alison Silva, President & Chief Executive Officer. “We look forward to continuing to provide updates at critical milestones as we advance COTI-2 through clinical development.”

Upcoming Milestones

COTI-2:

  • Dose first patient with combination therapy, COTI-2 plus cisplatin, in the Phase 1b/2a clinical trial in solid tumors;
  • Complete additional exploratory endpoint data analysis of the dose escalation portion of the gynecological malignancies Phase 1 trial;
  • Initiate breast cancer trial with COTI-2.

COTI-219:

  • Complete IND-enabling studies;
  • Finalize GMP manufacturing;
  • File an IND.

Corporate:

  • Strengthen the balance sheet;
  • Opportunistically pursue regional or co-development partnerships for COTI-2, pipeline programs and other technologies.

Financial Results

The Company’s operational activities during the quarter were primarily focused on advancing the Phase 1b/2a clinical trial of COTI-2.

For the three-months ended October 31, 2018, the Company incurred a net loss of $0.495 million, or $0.02 per share, compared to a net loss of $1.781 million, or $0.11 per share, for the three-months ended October 31, 2017.  The decrease in net loss during the three-month period is primarily due to decreases in Research and Development (R&D) expense and General and Administrative (G&A) expense.

For the six-months ended October 31, 2018, the Company incurred a net loss of $1.476 million, or $0.07 per share, compared to a net loss of $2.023 million, or $0.11 per share, for the six months ended October 31, 2017.  The decrease in net loss during the period is primarily due to decreases in R&D, Sales and Marketing (S&M) expense and G&A expense, offset by changes in fair value warrant liability.

There was no revenue for the three and six months ended October 31, 2018 or in the comparative periods in the prior year.

R&D expense in the three-month period ended October 31, 2018 decreased by $0.861 million over the same period in the prior year.  The decrease in R&D expense in the three-month period is primarily due to a decrease in salaries and benefits due to lower headcount and preclinical testing as Cotinga continues to work to initiate an expanded protocol for its ongoing Phase 1b/2 clinical trial of COTI-2.  For the six months ended October 31, 2018, R&D expense decreased by $1.144 million over the same period in the year prior.

S&M expense in the three-month period ended October 31, 2018 increased by $0.027 million over the same period in the year prior.  The increase in S&M expense in the three-month period is primarily due to an increase in marketing and product presentations.  For the six months ended October 31, 2018, S&M expense decreased by $0.021 million over the same period in the prior year due to cost reductions implemented last financial year.

G&A expense in the three-month period ended October 31, 2018 decreased by $0.391 million over the same period in the year prior.  The decrease in G&A expense in the three-month period is primarily due to a decrease in salaries due to lower head count; stream lining of corporate operations and lower share-based compensation.  For the six months ended October 31, 2018, G&A expense decreased by $0.677 million over the same period in the prior year.

Fair value of warrant liability for the six months ended October 31, 2018, decreased by $1.278 million over the same period in the year prior.

Detailed operating and financial results can be found in the Company’s Unaudited Condensed Interim Financial Statements and Management Discussion and Analysis for the three and six months ended October 31, 2018, which can be found on SEDAR at www.sedar.com or on the Company’s website at www.cotingapharma.com .

About Cotinga Pharmaceuticals Inc.

Cotinga Pharmaceuticals is a clinical-stage pharmaceutical company that uses proprietary artificial intelligence technologies to pursue a targeted and transformational approach to treating cancer and other unmet medical needs. Cotinga’s CHEMSAS® technology is intended to accelerate the discovery and development of novel drug therapies, allowing the Company to build a pipeline of potential drug candidates faster and with a higher probability of success than traditional methods.

The Company’s lead compound, COTI-2, has a novel p53-dependent mechanism of action with selective and potent anti-cancer activity. P53 mutations occur in over 50% of all cancers.  COTI-2 is initially being evaluated in combination with various standard of care chemotherapy regimens for the treatment of a wide spectrum of cancers in a Phase 1b/2a clinical trial at the MD Anderson Cancer Center at the University of Texas. The Company has secured orphan drug status in the United States for COTI‐2 for the treatment of ovarian cancer. Preclinical data suggests that COTI-2 could dramatically improve the treatment of cancers with mutations in the p53 gene.

The Company’s second lead compound, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS function. KRAS mutations occur in up to 30% of all cancers and represent a tremendous unmet clinical need and a desirable drug target. COTI-219 is undergoing IND-enabling studies to support a regulatory submission.

Follow @CotingaPharma on Twitter at http://twitter.com/CotingaPharma .

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information, visit http://www.cotingapharma.com/ or contact: Alison Silva President and CEO Tel: 1-800-798-6860 Email: asilva@cotingapharma.com

Notice to Readers:

Information contained in this press release may contain certain statements which constitute “forward-looking statements” as such term is defined under applicable securities laws. Forward‐looking statements by their nature are not guarantees of future performance and are based upon management’s current expectations, estimates, projections and assumptions. For example, statements in the “Upcoming Milestones” section are forward-looking statements. Cotinga operates in a highly competitive environment that involves significant risks and uncertainties, which could cause actual results to differ materially from those anticipated in these forward‐looking statements. Management of Cotinga considers the assumptions on which these forward‐looking statements are based to be reasonable, but as a result of the many risk factors, cautions the reader that actual results could differ materially from those expressed or implied in these forward-looking statements. Information in this press release should be considered accurate only as of the date of the release and may be superseded by more recent information disclosed in later press releases, filings with the securities regulatory authorities or otherwise. Except as required by law, Cotinga assumes no obligation to update forward-looking statements should circumstances or management's expectations, estimates, projections and assumptions change.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Chord's $550 Million Exit Tightens Its Basin Focus

Updated Category News Views 35

One map pin just disappeared from Chord Energy’s corporate wall, and that matters more than the usual deal-closing confetti. Chord has completed the sale of its entire non-operated Marcellus position to POSCO International for $550 million in gross consideration. For shareholders in NASDAQ:CHRD, this is not a flashy new drilling story. It is a cleanup job, and sometimes...

Continue Reading
Flair's New Aviation Alliance Offers Options, Not Orders

Updated Category News Views 55

Aircraft shortages have a funny way of turning vague partnerships into very useful insurance policies. Flair Airlines, Phoenix Aviation Capital and Avia Solutions Group announced a Strategic Commercial Cooperation Agreement on Nov. 19, 2026, and the sensible reading is straightforward: the Canadian value carrier wants more ways to solve capacity and operational problems...

Continue Reading
Great Rail Journeys Bets Bigger on Luxury Rail in 2027

Updated Category News Views 99

A $19,995 vacation is not selling a seat on a train; it is selling relief from planning, crowds and compromise. Great Rail Journeys is leaning hard into that proposition for 2027 with two additions to its premium Landmark Collection: a Europe-heavy Orient Express and Rhône cruise pairing, plus a South Africa itinerary built around safari, Victoria Falls and rail-flavored...

Continue Reading
PayPal's New Leadership Map Puts Execution on Trial

Updated Category News Views 83

Four senior appointments and a risk-chief exit can turn a tidy strategy slide into a very real operating test. PayPal has spent months defining three-year plans, simplifying its operating model and assigning clearer accountability; on November 20, it put names beside the jobs. For NASDAQ:PYPL investors, that is more consequential than another broad promise about...

Continue Reading
Digital Diabetes Care Has a Bigger Prize Than Devices

Updated Category News Views 121

A glucose sensor is becoming less a gadget than a running conversation between patient, clinician and software. That shift matters because diabetes management is leaving the occasional clinic visit and moving into daily life, where the useful product is not merely a reading but a pattern someone can act on. The sector deserves attention from investors, but it also...

Continue Reading
S&P Global's UBS AI Conference Slot Deserves Attention

Updated Category News Views 80

Thirty Minutes Can Still Matter A half-hour fireside chat is not a quarterly earnings call, and anybody treating it like one is setting themselves up for disappointment. Still, S&P Global CEO Martina Cheung appearing at the UBS Global Technology and AI Conference on December 2 deserves a spot on the calendar for owners of NYSE:SPGI. This is a company sitting in the middle...

Continue Reading
Automus and Google Cloud Put Agents to Work on Oracle

Updated Category News Views 96

Oracle back offices are where shiny AI promises go to earn their keep, or get buried under a mountain of integrations. Automus Consulting’s newly announced collaboration with Google Cloud, unveiled November 20 at Oracle AI World, is aimed squarely at that messy middle. The firm wants to combine its Oracle implementation experience with Google Cloud infrastructure and...

Continue Reading
GEYOTO’s RE+ Debut Shows Demand, Not Yet Scale Proof

Updated Category News Views 5

Desert-colored booths do not pay invoices, but a nearly sold-out stash of spare units is a lot more useful than the usual trade-show applause. GEYOTO’s first RE+ appearance, held November 17–19 at the Las Vegas Convention Center, produced the kind of early evidence a young energy-products brand needs: people stopped, handled the equipment, asked questions, made...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 55

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
Trump's Reagan Forum Speech Puts Defense in Focus Again

Updated Category News Views 92

A December podium in Simi Valley has suddenly become a market-relevant appointment. The Ronald Reagan Presidential Foundation and Institute says President Donald J. Trump will deliver the keynote at the 2026 Reagan National Defense Forum on Friday, December 4, at 3:00 p.m. Pacific time, or 6:00 p.m. Eastern. That is the whole hard fact pattern so far. No agenda, no...

Continue Reading

Top 5 Most Recently Viewed Articles

BGSF Stock Declines as Company Reassesses Market Strategies

Updated Category News Views 181

BGSF Faces Market Headwinds as Stock Hits 52-Week Low In the midst of a tough market landscape, BG Staffing Inc (NYSE: BGSF) has seen its stock hit a 52-week low, dropping to $5.13. This decline mirrors a significant reduction in share value, with a notable 44.7% decrease over the past year. The current economic climate has prompted a cautious approach among investors,...

Continue Reading
Datadog's Earnings Predictions and Market Outlook for 2025

Updated Category News Views 254

What to Expect from Datadog's Earnings Announcement Datadog (NASDAQ: DDOG) is gearing up to announce its latest quarterly earnings, generating considerable interest among investors. Understanding the key metrics and expectations surrounding this event can be crucial for those looking to navigate the market effectively. Analysts' Expectations for Earnings Analysts...

Continue Reading
Investors Can Join Metagenomi, Inc. Securities Class Action

Updated Category News Views 245

Understanding Opportunities for Metagenomi, Inc. Investors Investing in stocks, especially during an initial public offering (IPO), carries risks, but it also presents unique opportunities. If you have purchased shares of Metagenomi, Inc. (NASDAQ: MGX), you might be eligible for compensation as part of a class action lawsuit. This opportunity has been highlighted by...

Continue Reading
Recent Market Trends and Insights on MongoDB Options Movements

Updated Category News Views 139

A Deep Dive into MongoDB's Options Activity Recently, attention has shifted towards MongoDB (NASDAQ: MDB), as financial giants display significant bearish moves that have piqued the interest of traders and analysts alike. An examination of MongoDB's options activity has unveiled a notable pattern, indicating varied sentiments in the market. In the latest analysis, we...

Continue Reading
Sotherly Hotels Inc. Revises Dividend Tax Treatment Details

Updated Category News Views 112

Understanding Recent Changes in Dividend Tax Treatment Sotherly Hotels Inc. (NASDAQ: SOHO), a notable player in the lodging industry, has recently announced amendments regarding the estimated income tax classification for its 2024 distributions related to the Series D preferred shares. This revision, first mentioned on February 18, arises from inaccuracies found in the...

Continue Reading